RxDoctor Payments Data

Timothy Arling, MD

Internal Medicine · Chevy Chase, MDNPI 1588930234

Payments from drug & device makers

$5,279in general payments, 2019–2025

Across 245 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$905
  • AbbVie$795
  • Pfizer$566
  • Lilly USA, LLC$429
  • Amgen$375
  • Merck$128
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,264100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,279 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$201,773
Medicare patients
444
Services billed
2,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$164,936
OzempicSemaglutide85$89,163
JardianceEmpagliflozin36$56,085
XareltoRivaroxaban47$48,553
ProliaDenosumab22$38,082
FarxigaDapagliflozin Propanediol38$33,035
MyrbetriqMirabegron31$27,820
MounjaroTirzepatide15$16,274
NucyntaTapentadol Hcl13$15,697
JanuviaSitagliptin Phosphate16$12,684
NexlizetBempedoic Acid/Ezetimibe18$11,586
Atorvastatin Calcium448$6,077
PaxlovidNirmatrelvir/Ritonavir60$5,651
Rosuvastatin Calcium223$4,780
SynthroidLevothyroxine Sodium71$4,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$566$170,587193 claims
Novo NordiskOzempic$905$89,16385 claims
Boehringer IngelheimJardiance$94$56,08536 claims
Johnson & JohnsonXarelto$26$48,55347 claims
AmgenProlia$375$38,08222 claims
AstraZenecaFarxiga$65$33,03538 claims
Astellas Pharma US IncMyrbetriq$74$27,82031 claims
Lilly USA, LLCMounjaro$429$16,27415 claims
MerckJanuvia$128$12,68416 claims
Esperion Therapeutics, Inc.Nexlizet$76$11,58618 claims
AbbVieSynthroid$795$4,53271 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$2,666170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →